Log In
Print this Print this

subcutaneous beloranib (CKD-732, ZGN-440)

  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionSubcutaneous formulation of a methionine aminopeptidase 2 (MetAP2) inhibitor
Molecular Target Methionine aminopeptidase 2 (MetAP2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationObesity
Indication DetailsTreat obesity; Treat Prader-Willi syndrome
Regulatory Designation

U.S. - Orphan Drug (Treat Prader-Willi syndrome);
EU - Orphan Drug (Treat Prader-Willi syndrome)


Zafgen Inc.

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today